Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director · President and CEO · 10% owner | July 06, 2026 | July 09, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Director | February 17, 2017 | February 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date July 06, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,261,671 |
Reported balance
After 2026-07-06 transaction · row 1
1 source rowRow 1 · 2026-07-06 · Sale · Disposed 44,058 · Balance 7,261,671 F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020.
Radius Health, Inc.
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16 | Direct | 27,500 |
Reported balance
After 2017-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 7, 2021 01:05 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 18,235 | $10.22 | $186,379.94 |
DisclosureSEC source: 0001209191-21-002383 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,284,258 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:32 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 355 | $11.66 | $4,137.88 |
DisclosureSEC source: 0001209191-20-061807 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,302,493 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 371 | $7.82 | $2,899.40 |
DisclosureSEC source: 0001209191-20-056783 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,302,848 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.810 to $7.817, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 22:13 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 350 | $10.13 | $3,544.80 |
DisclosureSEC source: 0001209191-20-053855 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303,219 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 347 | $9.78 | $3,393.35 |
DisclosureSEC source: 0001209191-20-049479 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303,569 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 330 | $10.79 | $3,560.70 |
DisclosureSEC source: 0001209191-20-045117 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303,916 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 23:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 2,607 | $10.66 | $27,802.61 |
DisclosureSEC source: 0001209191-20-041291 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,304,246 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.62 to $10.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 242 | $10.71 | $2,591.82 |
DisclosureSEC source: 0001209191-20-034443 · doc4.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,306,853 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 100 | $10.70 | $1,070.10 |
DisclosureSEC source: 0001209191-20-034443 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307,095 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 339 | $9.70 | $3,288.71 |
DisclosureSEC source: 0001209191-20-027502 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307,195 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:39 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 347 | $7.39 | $2,562.60 |
DisclosureSEC source: 0001209191-20-023177 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307,534 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:38 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 372 | $10.02 | $3,725.62 |
DisclosureSEC source: 0001209191-20-015236 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307,881 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 00:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 161,649 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001209191-20-009433 · doc4.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,649 Underlying: COMMON STOCK · 161,649 shares Expires 2030-02-10 F3 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is January 1, 2020. Subject to the Reporting Person's continued status as an employee of the Issuer, the option shall vest and become exercisable with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Vesting Commencement Date, and with respect to an additional 1/36th shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter. Additionally, if the Reporting Person experiences a Termination of Service by the Issuer without Cause or by the Reporting Person with Good Reason, each as defined in the employment agreement between the Issuer and the Reporting Person dated January 19, 2012 (the "Employment Agreement"), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, as defined in the Employment Agreement, F4 · derivative.exercise_date: (continued from footnote 1 above) then (subject to timely executing and not revoking the Release Agreement (as defined in the Employment Agreement)) (i) the option shall vest and become exercisable in full on the later to occur of such termination or the Change in Control, and (ii) the option shall remain exercisable until the earlier to occur of the first anniversary of such termination or the expiration date of the option reported herein. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 00:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 127,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009433 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,308,253 F1 · shares: Represents Restricted Stock Units which vest (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the vesting commencement date of January 1, 2020 ("Vesting Commencement Date"), and (ii) with respect to an additional 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Additionally, if the Reporting Person experiences a Termination of Service by the Issuer without Cause or by the Reporting Person with Good Reason, each as defined in the employment agreement between the Issuer and the Reporting Person dated January 19, 2012 (the "Employment Agreement"), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, as defined in the Employment Agreement, (continued in Footnote 2 below) F2 · shares: (continued from Footnote 1 above) then (subject to timely executing and not revoking the Release Agreement (as defined in the Employment Agreement)) the restricted stock units shall vest ain full on the later to occur of such termination or the Change in Control. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 22:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 331 | $8.01 | $2,652.80 |
DisclosureSEC source: 0001209191-20-006479 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,180,700 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:47 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 5,973 | $8.39 | $50,113.47 |
DisclosureSEC source: 0001209191-20-001102 · doc4.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,181,031 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:47 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 43 | $8.32 | $357.76 |
DisclosureSEC source: 0001209191-20-001102 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187,004 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 455 | $10.33 | $4,699.65 |
DisclosureSEC source: 0001209191-19-058737 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187,047 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:31 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 100 | $7.40 | $740.01 |
DisclosureSEC source: 0001209191-19-055207 · doc4.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187,502 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:31 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 378 | $7.40 | $2,797.20 |
DisclosureSEC source: 0001209191-19-055207 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187,602 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:32 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 504 | $9.97 | $5,027.15 |
DisclosureSEC source: 0001209191-19-052215 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187,980 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 20:38 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 524 | $10.14 | $5,313.36 |
DisclosureSEC source: 0001209191-19-048772 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188,484 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 22:24 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1 | $9.01 | $9.01 |
DisclosureSEC source: 0001209191-19-044685 · doc4.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189,008 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 22:24 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 516 | $9.03 | $4,659.48 |
DisclosureSEC source: 0001209191-19-044685 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189,009 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 20:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 12,715 | $9.98 | $126,846.11 |
DisclosureSEC source: 0001209191-19-043048 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 22:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 495 | $12.78 | $6,326.10 |
DisclosureSEC source: 0001209191-19-041275 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,202,240 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 483 | $15.18 | $7,331.94 |
DisclosureSEC source: 0001209191-19-034818 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,202,735 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 477 | $32.38 | $15,445.31 |
DisclosureSEC source: 0001209191-19-027722 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,203,218 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 491 | $35.79 | $17,573.09 |
DisclosureSEC source: 0001209191-19-023260 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,203,695 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.78 to $35.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 04, 2019 Filed Mar 22, 2019 20:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 496 | $38.62 | $19,155.52 |
DisclosureSEC source: 0001209191-19-021011 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,204,186 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 62,634 | $0.00 Strike: $27.76 | $0.00 |
DisclosureSEC source: 0001209191-19-008680 · doc4.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,634 Underlying: COMMON STOCK · 62,634 shares Expires 2029-02-05 F2 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2019 ("Option Vesting Commencement Date"). The option vests (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Option Vesting Commencement Date and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Option Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 39,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008680 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,204,682 F1 · shares: Represents Restricted Stock Units which vest (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the vesting commencement date of January 1, 2019 ("RSU Vesting Commencement Date"), and (ii) with respect to an additional 1/6th of the shares subject thereto on each six-month anniversary of the RSU Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 345 | $27.80 | $9,591.00 |
DisclosureSEC source: 0001209191-19-007740 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,165,467 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:44 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 8,825 | $24.74 | $218,334.03 |
DisclosureSEC source: 0001209191-19-005177 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,165,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.55 to $24.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:26 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 4,424 | $20.67 | $91,444.08 |
DisclosureSEC source: 0001209191-19-002246 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,174,637 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 21:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 12,520 | $52.00 | $651,019.97 |
DisclosureSEC source: 0001209191-18-043755 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179,061 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2018 Filed Feb 13, 2018 22:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 56,940 | $0.00 Strike: $60.85 | $0.00 |
DisclosureSEC source: 0001209191-18-009703 · doc4.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,940 Underlying: COMMON STOCK · 56,940 shares Expires 2028-02-10 F2 · derivative.exercise_date: The vesting commencement date of the option is January 1, 2018 ("Vesting Commencement Date"). The option vests (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 11, 2018 Filed Feb 13, 2018 22:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 35,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009703 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,191,581 F1 · shares: Represents Restricted Stock Units which vest (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the vesting commencement date of January 1, 2018 ("Vesting Commencement Date"), and (ii) with respect to an additional 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:30 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 10,692 | $92.75 | $991,683.00 |
DisclosureSEC source: 0001209191-18-005125 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,155,931 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 21:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 4,000 | $95.60 | $382,400.00 |
DisclosureSEC source: 0001209191-17-046087 · doc4.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,166,623 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 21:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 9,175 | $94.34 | $865,605.28 |
DisclosureSEC source: 0001209191-17-046087 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,170,623 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions with one transaction pricing at $94.10 and the other transaction pricing at $94.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth in this footnote. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:22 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013228 · doc4.xml · derivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:39 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 70,000 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-17-012738 · doc4.xml · derivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: COMMON STOCK · 70,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is February 16, 2017. Subject to the Reporting Person's continued status as an employee of the Issuer, the option shall vest and become exercisable with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Vesting Commencement Date, and with respect to an additional 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter; (continued to Footnote 2 below) F2 · derivative.exercise_date: (Continued from Footnote 1 above) provided, however, that if the Reporting Person experiences a Termination of Service by the Issuer without Cause or by the Reporting Person with Good Reason, each as defined in the employment agreement between the Issuer and the Reporting Person dated January 19, 2012 (the "Employment Agreement"), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, as defined in the Employment Agreement, then (subject to timely executing and not revoking the Release Agreement (as defined in the Employment Agreement)) (i) the option shall vest and become exercisable in full on the later to occur of such termination or the Change in Control, and (ii) the option shall remain exercisable until the earlier to occur of the first anniversary of such termination or the expiration date of the option reported herein. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 10,202 | $33.24 | $339,064.49 |
DisclosureSEC source: 0001209191-17-005343 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179,798 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 14, 2016 Filed Oct 15, 2016 01:09 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-145977 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,190,000 F1 · shares: Represents Restricted Stock Units which vest in six substantially equal installments on each six-month anniversary of the Vesting Commencement Date of July 19, 2016, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.